ES2174868T3 - Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico. - Google Patents

Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.

Info

Publication number
ES2174868T3
ES2174868T3 ES94902198T ES94902198T ES2174868T3 ES 2174868 T3 ES2174868 T3 ES 2174868T3 ES 94902198 T ES94902198 T ES 94902198T ES 94902198 T ES94902198 T ES 94902198T ES 2174868 T3 ES2174868 T3 ES 2174868T3
Authority
ES
Spain
Prior art keywords
tgf
beta
fragment
tipoii
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94902198T
Other languages
English (en)
Inventor
Patricia R Segarini
James R Dasch
David R Olsen
Pedro A Carrillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2174868T3 publication Critical patent/ES2174868T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)

Abstract

SE DESCRIBE UN METODO DE TRATAMIENTO DEL EXCESO DE TGF BETA. EL TRATAMIENTO ES PARENTERAL, ORAL O POR MEDIO DE ADMINISTRACION TOPICA DE FRAGMENTOS DE RECEPTOR DE TGF - BETA. PARTICULARMENTE EFECTIVO ES UN FRAGMENTO SOLUBLE QUE PARECE LA PARTE EXTRACELULAR DE LA PROTEINA II DE ENLACE DEL TGF - BETA.
ES94902198T 1992-10-29 1993-10-29 Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico. Expired - Lifetime ES2174868T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96837592A 1992-10-29 1992-10-29
US3759793A 1993-03-26 1993-03-26

Publications (1)

Publication Number Publication Date
ES2174868T3 true ES2174868T3 (es) 2002-11-16

Family

ID=26714287

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94902198T Expired - Lifetime ES2174868T3 (es) 1992-10-29 1993-10-29 Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.

Country Status (8)

Country Link
US (1) US5693607A (es)
EP (1) EP0669833B1 (es)
JP (1) JPH08504763A (es)
AU (1) AU669256B2 (es)
CA (1) CA2146973C (es)
DE (1) DE69332026T2 (es)
ES (1) ES2174868T3 (es)
WO (1) WO1994009815A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US7384634B2 (en) 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2122491A1 (en) * 1991-10-31 1993-05-13 Herbert Y. Lin Tgf-.beta. type receptor cdnas and uses therefor
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU688409B2 (en) * 1993-11-19 1998-03-12 University Of Sydney, The A method for preventing or controlling cataract
EP0735895B1 (en) * 1993-11-19 2006-01-18 The University Of Sydney A method for preventing or controlling cataract
US5866323A (en) * 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
ATE366816T1 (de) * 1997-04-18 2007-08-15 Biogen Idec Inc Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
BRPI0307070A2 (pt) * 2002-01-22 2019-03-26 Genzyme Corporation uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
JP5481028B2 (ja) * 2004-10-13 2014-04-23 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連リンパ増殖性障害を処置または予防するための方法
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP1998810A4 (en) 2006-03-13 2009-09-02 Univ Johns Hopkins INCREASE OF ENDOTHELIAL THROMBORESISTENTEN
PL2918288T3 (pl) 2006-10-03 2018-02-28 Genzyme Corporation Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej
EP2171062A1 (en) * 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US8946201B2 (en) * 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
CN102159219B (zh) * 2008-09-16 2015-06-24 圣路易斯大学 提高转化生长因子-β信号发送的方法
US8911736B2 (en) 2010-03-12 2014-12-16 Genzyme Corporation Combination therapy for treating breast cancer
KR20130131414A (ko) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 ｉＰＳ 세포와 그 제조법
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
ES2917222T3 (es) 2011-12-28 2022-07-07 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
JP7231553B2 (ja) 2017-03-02 2023-03-01 ナショナル リサーチ カウンシル オブ カナダ Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用
CN110785431B (zh) 2017-05-04 2024-05-07 阿塞勒隆制药公司 TGF-β受体II型融合蛋白及其用途
UA128306C2 (uk) 2017-05-12 2024-06-05 Джянгсу Хенгруй Медісін Ко., Лтд. ЗЛИТІ ПРОТЕЇНИ, ЯКІ МІСТЯТЬ РЕЦЕПТОР TGF-<font face="Symbol">b</font>, І ЇХ ФАРМАЦЕВТИЧНЕ ЗАСТОСУВАННЯ
CN112119157B (zh) 2018-03-06 2025-01-14 宾夕法尼亚大学董事会 前列腺特异性膜抗原car及其使用方法
BR112020017382A2 (pt) 2018-03-09 2021-01-26 Agenus Inc. anticorpos anti-cd73 e métodos de uso dos mesmos
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
KR102881644B1 (ko) 2018-11-09 2025-11-06 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 TGF-β 수용체 융합 단백질 약학적 조성물 및 이의 용도
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US12109235B2 (en) 2019-06-21 2024-10-08 Kite Pharma, Inc. TGF-beta receptors and methods of use
CN113968903A (zh) 2020-07-24 2022-01-25 迈威(上海)生物科技股份有限公司 TGF-β RII突变体及其融合蛋白
AU2022291365B2 (en) 2021-06-08 2026-03-12 Kite Pharma, Inc. Gpc3 binding molecules
AU2023210700A1 (en) 2022-01-28 2024-08-15 35Pharma Inc. Activin receptor type iib variants and uses thereof
EP4653010A1 (en) 2024-05-14 2025-11-26 35Pharma Inc. Activin receptor type iib traps for use in improving body composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
ATE247708T1 (de) * 1986-10-02 2003-09-15 Massachusetts Inst Technology Verfahren zur regulierung der metabolischen stabilität von proteinen
US5084384A (en) * 1987-04-23 1992-01-28 Monsanto Company Secretion of insulin-like growth factor-I
US5108919A (en) * 1988-06-24 1992-04-28 Genentech, Inc. Dna sequences encoding yeast ubiquitin hydrolase
CA2002011A1 (en) * 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
EP0647714B1 (en) * 1989-07-19 1997-12-29 Tonen Corporation Peptidyl prolyl-cis.trans-isomerase
IL98569A0 (en) * 1990-06-20 1992-07-15 Bristol Myers Squibb Co Pharmaceutical compositions containing tgf-b and antagonists thereof for modulating blood pressure
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2122491A1 (en) * 1991-10-31 1993-05-13 Herbert Y. Lin Tgf-.beta. type receptor cdnas and uses therefor
WO1993010215A1 (en) * 1991-11-15 1993-05-27 Memorial Sloan-Kettering Cancer Center Purified proteoglycan betaglycan, compositions, and methods
MX9301135A (es) * 1992-03-06 1993-09-01 Steven G Reed Metodo para tratar infecciones por patogeno de macrofago.
EP0684828A4 (en) * 1993-02-19 1996-08-07 Celtrix Pharma PROPAGATION OF STEM CELLS IN LONG-TERM CULTURES OF BONE MARBLE CELLS BY REALIZING T6F-BETA.
EP0637450A3 (en) * 1993-08-04 1995-04-05 Collagen Corp Method and composition for resuscitation of hereditary tissue.
WO1995010610A1 (en) * 1993-10-15 1995-04-20 La Jolla Cancer Research Foundation BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY

Also Published As

Publication number Publication date
DE69332026T2 (de) 2002-10-31
JPH08504763A (ja) 1996-05-21
EP0669833B1 (en) 2002-06-12
EP0669833A1 (en) 1995-09-06
WO1994009815A1 (en) 1994-05-11
AU5665094A (en) 1994-05-24
CA2146973A1 (en) 1994-05-11
CA2146973C (en) 2008-09-02
DE69332026D1 (de) 2002-07-18
US5693607A (en) 1997-12-02
AU669256B2 (en) 1996-05-30
EP0669833A4 (en) 1996-07-31

Similar Documents

Publication Publication Date Title
ES2174868T3 (es) Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
HN1998000155A (es) Medicamentos
NL300210I2 (nl) Humaan groeihormoon variant.
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
PT772451E (pt) Tratamento da diabetes mellitus tipo ii com antagonistas de amilina
PL353750A1 (en) Dosages for treatment with anti-erbb2 antibodies
BR0215281A (pt) Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores da função do receptor de hormÈnio nuclear
BE2012C001I2 (es)
PT797439E (pt) Utilizacao de pramipexote como agente neuroprotector
ES2173868T3 (es) Utilizacion de relaxina para la fabricacion de un medicamento destinado al tratamiento de enfermedades cardiovasculares.
ES2148247T3 (es) Procedimiento de preparacion de liofilizado de cetrorelix.
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
DE69133485D1 (de) Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie
CY1105482T1 (el) Χρηση της αζιθρομυκινης στην τοπικη αγωγη οφθαλμικων μολυνσεων
PT855916E (pt) Composicao farmaceutica contendo um estimulador de activina ou inibina
PT1082129E (pt) Metodo para o tratamento de disturbios da fertilidade
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
ES2180550T3 (es) Moleculas receptoras de la hormona de glycoproteina.
NO970178L (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
GB9924941D0 (en) Treatment of dyskinesia
WO1998032429A3 (en) P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing
SE8800461D0 (sv) Farmaceutisk komposition
PE20001466A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas como bloqueadores del canal de sodio
AR001141A1 (es) Composiciones limpiadores conteniendo blanqueador halogenado y mejoradores de blanqueador con reducción del mal olor en la piel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 669833

Country of ref document: ES